Royalty Pharma plc (RPRX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Royalty Pharma plc (RPRX) Bundle
Gain insight into your Royalty Pharma plc (RPRX) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with real (RPRX) data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Royalty Pharma plc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,814.3 | 2,122.0 | 2,289.5 | 2,237.2 | 2,354.6 | 2,518.3 | 2,693.4 | 2,880.7 | 3,081.1 | 3,295.3 |
| Revenue Growth, % | 0 | 16.96 | 7.89 | -2.28 | 5.24 | 6.95 | 6.95 | 6.95 | 6.95 | 6.95 |
| EBITDA | 2,647.1 | 1,683.5 | 1,453.7 | 928.6 | 1,887.3 | 1,835.8 | 1,963.5 | 2,100.0 | 2,246.0 | 2,402.2 |
| EBITDA, % | 145.91 | 79.34 | 63.5 | 41.51 | 80.15 | 72.9 | 72.9 | 72.9 | 72.9 | 72.9 |
| Depreciation | 23.9 | 23.1 | 23.0 | 5.7 | 395.1 | 103.0 | 110.1 | 117.8 | 126.0 | 134.7 |
| Depreciation, % | 1.32 | 1.09 | 1 | 0.25344 | 16.78 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 |
| EBIT | 2,623.2 | 1,660.5 | 1,430.7 | 922.9 | 1,492.2 | 1,739.5 | 1,860.4 | 1,989.8 | 2,128.2 | 2,276.2 |
| EBIT, % | 144.59 | 78.25 | 62.49 | 41.25 | 63.37 | 69.07 | 69.07 | 69.07 | 69.07 | 69.07 |
| Total Cash | 793.2 | 1,992.0 | 2,803.3 | 2,427.8 | 495.3 | 1,806.3 | 1,931.9 | 2,066.2 | 2,209.9 | 2,363.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 491.3 | 626.4 | 682.7 | 727.9 | 775.1 | 764.9 | 818.1 | 875.0 | 935.9 | 1,000.9 |
| Account Receivables, % | 27.08 | 29.52 | 29.82 | 32.54 | 32.92 | 30.37 | 30.37 | 30.37 | 30.37 | 30.37 |
| Inventories | .0 | 657.1 | .0 | .0 | .0 | 156.0 | 166.8 | 178.4 | 190.8 | 204.1 |
| Inventories, % | 0 | 30.97 | 0.0000000437 | 0.0000000447 | 0 | 6.19 | 6.19 | 6.19 | 6.19 | 6.19 |
| Accounts Payable | 11.2 | 10.8 | 5.6 | 7.9 | 15.2 | 11.9 | 12.7 | 13.6 | 14.6 | 15.6 |
| Accounts Payable, % | 0.61607 | 0.50778 | 0.24547 | 0.35339 | 0.64407 | 0.47335 | 0.47335 | 0.47335 | 0.47335 | 0.47335 |
| Capital Expenditure | -1,721.3 | 2,197.0 | .5 | 2,041.2 | .0 | -477.9 | -511.1 | -546.6 | -584.6 | -625.3 |
| Capital Expenditure, % | -94.88 | 103.53 | 0.02284378 | 91.24 | 0 | -18.98 | -18.98 | -18.98 | -18.98 | -18.98 |
| Tax Rate, % | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 | 33.25 |
| EBITAT | 2,502.9 | 483.1 | 551.9 | 171.8 | 996.0 | 864.3 | 924.4 | 988.7 | 1,057.5 | 1,131.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 325.4 | 1,910.6 | 1,171.1 | 2,175.7 | 1,351.2 | 340.4 | 460.3 | 492.3 | 526.5 | 563.1 |
| WACC, % | 5.96 | 5.12 | 5.24 | 4.99 | 5.6 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,018.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 574 | |||||||||
| Terminal Value | 16,969 | |||||||||
| Present Terminal Value | 13,055 | |||||||||
| Enterprise Value | 15,073 | |||||||||
| Net Debt | 5,658 | |||||||||
| Equity Value | 9,415 | |||||||||
| Diluted Shares Outstanding, MM | 603 | |||||||||
| Equity Value Per Share | 15.62 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled real RPRX financials.
- Actual Data: Historical data alongside forward-looking estimates (highlighted in the yellow cells).
- Flexible Forecasting: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Royalty Pharma's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for clarity and user-friendliness, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life RPRX Financials: Pre-filled historical and projected data for Royalty Pharma plc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Royalty Pharma’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Royalty Pharma’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Royalty Pharma data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Royalty Pharma’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Royalty Pharma plc (RPRX)?
- Accurate Data: Access to real Royalty Pharma financials ensures trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and clear step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Institutional Investors: Develop comprehensive valuation models to assess Royalty Pharma plc (RPRX) investment opportunities.
- Corporate Development Teams: Evaluate various valuation scenarios to inform strategic decisions.
- Financial Consultants: Deliver precise valuation analysis and insights for clients interested in Royalty Pharma plc (RPRX).
- Academic Researchers: Utilize real-time data to study and teach financial modeling techniques.
- Pharmaceutical Analysts: Gain insights into how companies like Royalty Pharma plc (RPRX) are valued within the biotech sector.
What the Template Contains
- Pre-Filled Data: Includes Royalty Pharma plc’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Royalty Pharma plc’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.